7 min read · May 2026
Medicare GLP-1 Bridge Program: $50/Month Starting July 2026
Key update: Medicare Part D will cover FDA-approved GLP-1 medications for obesity starting July 1, 2026. The BALANCE Model caps patient copays at $50/month and has been extended through 2027.
For the first time in Medicare's history, obesity medications will be covered. The BALANCE Model (Beneficiary Access to Lifechanging Anti-obesity and Nutrition Care Explored) launches July 1, 2026, bringing brand-name GLP-1 coverage to millions of eligible beneficiaries at a fraction of retail cost.
BALANCE Model Basics
Participating Medicare Part D plans will cover FDA-approved anti-obesity medications — including Wegovy (semaglutide), Zepbound (tirzepatide), oral Wegovy, and Wegovy HD — with a beneficiary copay capped at $50 per month.
This represents savings of 95%+ compared to cash-pay pricing. For context, Wegovy's list price is approximately $1,349/month. Zepbound runs about $1,060/month. Under BALANCE, both cost $50.
Who Qualifies
Eligibility requires enrollment in a participating Part D plan plus a clinical indication for anti-obesity medication: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnea, dyslipidemia).
Critical detail: BALANCE covers only FDA-approved brand-name medications. Compounded semaglutide and tirzepatide are not eligible.
How to Prepare Before July 1
The smartest move is to have your prescription ready before launch day so you can fill on or shortly after July 1.
Step 1: Confirm your Part D plan is participating. Call the member services number on your card or check CMS.gov for the updated list of participating plans.
Step 2: Get a prescription. This requires a clinical evaluation — your PCP can do this, or use a telehealth platform that accepts Medicare.
Step 3: Establish baseline labs (A1C, lipid panel, metabolic panel). These document medical necessity if prior authorization is required.
Step 4: Fill on or after July 1, 2026. Prescriptions filled before that date won't receive the BALANCE copay cap.
If You're Not Medicare-Eligible
For patients under 65 without Medicare, compounded GLP-1 medications through telehealth remain the most affordable access point. Prices have dropped to $147-$350/month as provider competition intensifies.
Gala GLP-1
No dose-tier pricing increases. Transparent flat-rate pricing for compounded semaglutide.
Compounded medications are not FDA-approved.
Learn More Paid linkYucca Health
Compounded semaglutide and tirzepatide with the deepest commitment-plan discounts.
Compounded medications are not FDA-approved.
Learn More Paid linkSesame Care
For Medicare-eligible patients: prescribes brand-name FDA-approved medications compatible with BALANCE coverage.
Compare GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- CMS. "BALANCE Model." cms.gov, 2026.
- KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." May 2026.
- NPR. "Medicare to launch weight loss drug option in July with $50 copay." May 2026.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.